Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

BACKGROUND: Sixty percent of patients with stage IV melanoma may develop brain metastases, which result in significantly increased morbidity and a poor overall prognosis. Phase 3 studies of melanoma usually exclude patients with untreated brain metastases; therefore, clinical data for intracranial r...

Descripción completa

Detalles Bibliográficos
Autores principales: Holbrook, Kourtney, Lutzky, Jose, Davies, Michael A., Davis, Jessica Michaud, Glitza, Isabella C., Amaria, Rodabe N., Diab, Adi, Patel, Sapna P., Amin, Asim, Tawbi, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004095/
https://www.ncbi.nlm.nih.gov/pubmed/31658370
http://dx.doi.org/10.1002/cncr.32547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004095/
https://www.ncbi.nlm.nih.gov/pubmed/31658370
http://dx.doi.org/10.1002/cncr.32547

Ejemplares similares